U
HTG Molecular Diagnostics, Inc.
HTGMQ
$0.0001
$0.000.00%
E
Sell
12/11/2023Downgrade
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E+ from D- on 12/11/2023 due to a noticeable decline in the volatility index.
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E+ from D- on 12/11/2023 due to a noticeable decline in the volatility index.
D
Sell
11/24/2023Upgraded
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index and growth index. Earnings per share increased from -$4.4727 to -$2.283.
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D- from E+ on 11/24/2023 due to an increase in the volatility index and growth index. Earnings per share increased from -$4.4727 to -$2.283.
E
Sell
3/14/2023Downgrade
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E+ from D- on 03/14/2023.
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/1/2023Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 3/1/2023 due to a decline in the volatility index and growth index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 3/1/2023 due to a decline in the volatility index and growth index.
D
Sell
2/10/2023Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, valuation index and total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index, valuation index and total return index.
D
Sell
1/27/2023Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 1/27/2023 due to an increase in the valuation index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 1/27/2023 due to an increase in the valuation index and volatility index.
D
Sell
12/21/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 12/21/2022 due to a decline in the valuation index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 12/21/2022 due to a decline in the valuation index and volatility index.
D
Sell
12/6/2022Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 12/6/2022 due to an increase in the valuation index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 12/6/2022 due to an increase in the valuation index.
D
Sell
11/21/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/21/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 2.38 to 7.87, the quick ratio declined from 1.51 to 1.1, and total revenue declined 16.14% from $1.49M to $1.25M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/21/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 2.38 to 7.87, the quick ratio declined from 1.51 to 1.1, and total revenue declined 16.14% from $1.49M to $1.25M.
D
Sell
8/15/2022Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index. Earnings per share increased from -$0.811 to -$0.5352, total revenue increased 25.93% from $1.18M to $1.49M, and EBIT increased 9.23% from -$6.25M to -$5.68M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index. Earnings per share increased from -$0.811 to -$0.5352, total revenue increased 25.93% from $1.18M to $1.49M, and EBIT increased 9.23% from -$6.25M to -$5.68M.
D
Sell
5/18/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 5/18/2022 due to a noticeable decline in the growth index. Operating cash flow declined 75.21% from -$3.39M to -$5.94M, total revenue declined 58.83% from $2.88M to $1.18M, and EBIT declined 26.89% from -$4.93M to -$6.25M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 5/18/2022 due to a noticeable decline in the growth index. Operating cash flow declined 75.21% from -$3.39M to -$5.94M, total revenue declined 58.83% from $2.88M to $1.18M, and EBIT declined 26.89% from -$4.93M to -$6.25M.
D
Sell
5/16/2022Upgraded
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D from E+ on 05/16/2022.
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D from E+ on 05/04/2022.
HTG Molecular Diagnostics, Inc. (HTGMQ) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 1.04 to 1.46, and the quick ratio declined from 3.38 to 2.42.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and solvency index. Debt to equity increased from 1.04 to 1.46, and the quick ratio declined from 3.38 to 2.42.
D
Sell
11/15/2021Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/15/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the solvency index and valuation index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the solvency index and valuation index.
D
Sell
6/9/2021Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 6/9/2021 due to an increase in the volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 6/9/2021 due to an increase in the volatility index.
D
Sell
5/24/2021Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 5/24/2021 due to a decline in the growth index and volatility index. Total revenue declined 44.44% from $2.58M to $1.44M, operating cash flow declined 22.62% from -$3.55M to -$4.35M, and EBIT declined 9.44% from -$4.02M to -$4.4M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 5/24/2021 due to a decline in the growth index and volatility index. Total revenue declined 44.44% from $2.58M to $1.44M, operating cash flow declined 22.62% from -$3.55M to -$4.35M, and EBIT declined 9.44% from -$4.02M to -$4.4M.
D
Sell
2/1/2021Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 2/1/2021 due to an increase in the volatility index, growth index and total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 2/1/2021 due to an increase in the volatility index, growth index and total return index.
D
Sell
12/28/2020Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 12/28/2020 due to a decline in the volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 12/28/2020 due to a decline in the volatility index.
D
Sell
12/8/2020Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 12/8/2020 due to an increase in the volatility index and valuation index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 12/8/2020 due to an increase in the volatility index and valuation index.
D
Sell
11/20/2020Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/20/2020 due to a noticeable decline in the valuation index, growth index and volatility index. Total revenue declined 9.48% from $1.96M to $1.78M, and EBIT declined 3.44% from -$5M to -$5.17M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 11/20/2020 due to a noticeable decline in the valuation index, growth index and volatility index. Total revenue declined 9.48% from $1.96M to $1.78M, and EBIT declined 3.44% from -$5M to -$5.17M.
D
Sell
5/1/2020Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and growth index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and growth index.
D
Sell
3/30/2020Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 3/30/2020 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.1511 to -$0.0689, net income increased 7.4% from -$4.74M to -$4.39M, and EBIT increased 6.63% from -$4.62M to -$4.31M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 3/30/2020 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.1511 to -$0.0689, net income increased 7.4% from -$4.74M to -$4.39M, and EBIT increased 6.63% from -$4.62M to -$4.31M.
E
Sell
3/20/2020Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 3/20/2020 due to a decline in the volatility index and total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 3/20/2020 due to a decline in the volatility index and total return index.
D
Sell
2/12/2020Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index and valuation index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index and valuation index.
E
Sell
11/13/2019Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 11/13/2019 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 28.3% from -$3.17M to -$4.07M, and total revenue declined 6.75% from $5.8M to $5.4M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 11/13/2019 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 28.3% from -$3.17M to -$4.07M, and total revenue declined 6.75% from $5.8M to $5.4M.
D
Sell
8/8/2019Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 8/8/2019 due to a decline in the volatility index, efficiency index and total return index. Total capital declined 13.68% from $26.75M to $23.09M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 8/8/2019 due to a decline in the volatility index, efficiency index and total return index. Total capital declined 13.68% from $26.75M to $23.09M.
D
Sell
5/15/2019Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 5/15/2019 due to a substantial decline in the growth index, total return index and solvency index. EBIT declined 157.49% from -$2.07M to -$5.32M, earnings per share declined from -$0.0746 to -$0.19, and operating cash flow declined 117.16% from -$2.58M to -$5.59M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 5/15/2019 due to a substantial decline in the growth index, total return index and solvency index. EBIT declined 157.49% from -$2.07M to -$5.32M, earnings per share declined from -$0.0746 to -$0.19, and operating cash flow declined 117.16% from -$2.58M to -$5.59M.
D
Sell
3/12/2019Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 3/12/2019 due to a noticeable increase in the growth index and volatility index. Total revenue increased 64.2% from $4.71M to $7.73M, EBIT increased 57.01% from -$4.8M to -$2.07M, and earnings per share increased from -$0.1703 to -$0.0767.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 3/12/2019 due to a noticeable increase in the growth index and volatility index. Total revenue increased 64.2% from $4.71M to $7.73M, EBIT increased 57.01% from -$4.8M to -$2.07M, and earnings per share increased from -$0.1703 to -$0.0767.
D
Sell
2/7/2019Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 2/7/2019 due to a decline in the total return index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 2/7/2019 due to a decline in the total return index and volatility index.
D
Sell
12/24/2018Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 12/24/2018 due to an increase in the total return index and efficiency index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 12/24/2018 due to an increase in the total return index and efficiency index.
D
Sell
8/14/2018Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 8/14/2018 due to a decline in the growth index, efficiency index and valuation index. Operating cash flow declined 59.38% from -$2.7M to -$4.31M, and total capital declined 9.16% from $40.52M to $36.81M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D from D+ on 8/14/2018 due to a decline in the growth index, efficiency index and valuation index. Operating cash flow declined 59.38% from -$2.7M to -$4.31M, and total capital declined 9.16% from $40.52M to $36.81M.
D
Sell
2/14/2018Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 2/14/2018 due to a major increase in the total return index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D+ from D on 2/14/2018 due to a major increase in the total return index and volatility index.
D
Sell
11/8/2017Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/8/2017 due to a noticeable increase in the growth index and efficiency index. Total revenue increased 111.47% from $1.76M to $3.72M, earnings per share increased from -$0.5979 to -$0.4637, and operating cash flow increased 16.21% from -$4.96M to -$4.15M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/8/2017 due to a noticeable increase in the growth index and efficiency index. Total revenue increased 111.47% from $1.76M to $3.72M, earnings per share increased from -$0.5979 to -$0.4637, and operating cash flow increased 16.21% from -$4.96M to -$4.15M.
D
Sell
8/14/2017Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D+ on 8/14/2017 due to a significant decline in the efficiency index, total return index and solvency index. Net income declined 0.42% from -$5.82M to -$5.84M.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D+ on 8/14/2017 due to a significant decline in the efficiency index, total return index and solvency index. Net income declined 0.42% from -$5.82M to -$5.84M.
D
Sell
7/26/2017Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D+ from C- on 7/26/2017 due to a noticeable decline in the total return index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D+ from C- on 7/26/2017 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/24/2017Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to C- from D- on 5/24/2017 due to a significant increase in the efficiency index, total return index and volatility index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to C- from D- on 5/24/2017 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
3/24/2017Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 3/24/2017 due to a noticeable decline in the efficiency index, growth index and solvency index. Debt to equity increased from -5.94 to -2.11, total capital declined 43.47% from $10.94M to $6.19M, and the quick ratio declined from 1.76 to 1.32.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to D- from D on 3/24/2017 due to a noticeable decline in the efficiency index, growth index and solvency index. Debt to equity increased from -5.94 to -2.11, total capital declined 43.47% from $10.94M to $6.19M, and the quick ratio declined from 1.76 to 1.32.
D
Sell
11/16/2016Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/16/2016 due to an increase in the efficiency index, solvency index and valuation index. Debt to equity declined from 3.61 to -5.94, and net income increased 5.3% from -$6.85M to -$6.49M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D from D- on 11/16/2016 due to an increase in the efficiency index, solvency index and valuation index. Debt to equity declined from 3.61 to -5.94, and net income increased 5.3% from -$6.85M to -$6.49M.
D
Sell
11/1/2016Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 11/1/2016 due to an increase in the valuation index and total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 11/1/2016 due to an increase in the valuation index and total return index.
E
Sell
10/13/2016Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 10/13/2016 due to a decline in the valuation index.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 10/13/2016 due to a decline in the valuation index.
D
Sell
9/20/2016Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 9/20/2016 due to an increase in the volatility index and total return index.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 9/20/2016 due to an increase in the volatility index and total return index.
E
Sell
8/10/2016Downgrade
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 8/10/2016 due to a major decline in the volatility index, solvency index and total return index. Debt to equity increased from 1.49 to 3.61, and the quick ratio declined from 2.93 to 2.35.
HTG Molecular Diagnostics, Inc. (HTGM) was downgraded to E+ from D- on 8/10/2016 due to a major decline in the volatility index, solvency index and total return index. Debt to equity increased from 1.49 to 3.61, and the quick ratio declined from 2.93 to 2.35.
D
Sell
2/1/2016Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index. Total revenue increased 27.88% from $790.6 to $1.01M, and EBIT increased 2.14% from -$4.72M to -$4.83M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to D- from E+ on 2/1/2016 due to an increase in the growth index. Total revenue increased 27.88% from $790.6 to $1.01M, and EBIT increased 2.14% from -$4.72M to -$4.83M.
E
Sell
11/2/2015Upgraded
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to E+ from E on 11/2/2015 due to a noticeable increase in the solvency index, total return index and growth index. The quick ratio increased from 0.37 to 8.78, debt to equity declined from -0.17 to 0.39, and operating cash flow increased 30.97% from -$4.41M to -$5.78M.
HTG Molecular Diagnostics, Inc. (HTGM) was upgraded to E+ from E on 11/2/2015 due to a noticeable increase in the solvency index, total return index and growth index. The quick ratio increased from 0.37 to 8.78, debt to equity declined from -0.17 to 0.39, and operating cash flow increased 30.97% from -$4.41M to -$5.78M.
E
Sell
7/31/2015None
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E from U on 07/31/2015.
HTG Molecular Diagnostics, Inc. (HTGMQ) was downgraded to E from U on 07/31/2015.
OTC PK
03/13/2025 9:42AM Eastern
Quotes delayed
